FACULTY | Chair
Massimo Colombo, MD
University of Milan
Milan, Italy
Faculty
Ghassan Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
René Adam, MD, PhD
Paul Brousse Hospital
Villejuif, France
Laura Crocetti, MD, PhD
University of Pisa
Pisa, Italy
Philip Johnson, MD, FRCP
University of Birmingham
Birmingham, United Kingdom
Hans Christian Spangenberg, MD
University of Freiburg
Freiburg, Germany
Jessica Zucman-Rossi, MD, PhD
University Paris Descartes
Paris, France |
Target Audience | This educational activity is designed for pan-European medical oncologists, hepatologists, surgical oncologists, radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with hepatocellular carcinoma. This meeting is restricted to healthcare professionals based outside of the United States. |
|
|
 |
|
Expert Discussion
|
 |
|
Downloadable Slides
|
|
 |
|
TOPICS | Risk of HCC and role of screening and surveillance
Philip Johnson, MD, FRCP
Multidisciplinary management of HCC: An evolving story
Massimo Colombo, MD
Molecular classification of HCC: Importance of translational research
Jessica Zucman-Rossi, MD, PhD
Keynote Lecture:
Targeting signaling pathways in HCC: Novel molecular targeted therapies on the horizon
Ghassan Abou-Alfa, MD
Case #1—Management of early-stage HCC
René Adam, MD, PhD, and faculty panel
Case #2—Locoregional therapy for intermediate stage HCC: A practical approach to patient management
Laura Crocetti, MD, PhD, and faculty panel
Case #3—Advanced unresectable HCC: A multidisciplinary clinicopathologic conference
Hans Christian Spangenberg, MD, and faculty panel
Case #4—Treatment options for a patient with pretreated HCC: A multidisciplinary clinicopathologic conference
Philip Johnson, MD, FRCP, and faculty panel |
LEARNING OBJECTIVES | Upon completion of this educational activity, participants should be able to:
- Discuss the epidemiology and risk factors for hepatocellular carcinoma (HCC), and discuss strategies for screening and surveillance
- Examine the current understanding of HCC tumor biology with regard to gene profiling, molecular targets, biomarkers, and risk-assessment strategies
- Describe current standards of care and recent advances in the treatment of advanced unresectable HCC, including the role of targeted therapies, patient selection, and appropriate response-monitoring strategies
- Discuss the efficacy and safety of treatment options for patients with metastatic HCC beyond first-line therapy, including chemotherapy and novel targeted agents
- Identify the importance of a multidisciplinary approach in the treatment of patients with HCC
- Evaluate the latest treatment approaches for early-stage and intermediate-stage HCC, including diagnostic procedures, radiation and embolization techniques, and surgical strategies.
|
|
|
|
Organizer | This is a prIME Oncology activity.
|
Support | Support for this educational activity has been provided by Bristol-Myers Squibb.
|
|
